Abstract
Prostate cancer is one of the most common cancers globally and is the second most common cancer in the male population in the US. Here we develop a study based on correlating the hematoxylin and eosin (H&E)-stained biopsy data with MALDI mass-spectrometric imaging data of the corresponding tissue to determine the cancerous regions and their unique chemical signatures and variations of the predicted regions with original pathological annotations. We obtain features from high-resolution optical micrographs of whole slide H&E stained data through deep learning and spatially register them with mass spectrometry imaging (MSI) data to correlate the chemical signature with the tissue anatomy of the data. We then use the learned correlation to predict prostate cancer from observed H&E images using trained coregistered MSI data. This multimodal approach can predict cancerous regions with ∼80% accuracy, which indicates a correlation between optical H&E features and chemical information found in MSI. We show that such paired multimodal data can be used for training feature extraction networks on H&E data which bypasses the need to acquire expensive MSI data and eliminates the need for manual annotation saving valuable time. Two chemical biomarkers were also found to be predicting the ground truth cancerous regions. This study shows promise in generating improved patient treatment trajectories by predicting prostate cancer directly from readily available H&E-stained biopsy images aided by coregistered MSI data.
Original language | English |
---|---|
Pages (from-to) | 227-235 |
Number of pages | 9 |
Journal | Journal of the American Society for Mass Spectrometry |
Volume | 34 |
Issue number | 2 |
DOIs | |
State | Published - Feb 1 2023 |
Funding
This research is supported by the Office of Research and Development, Veterans Health Administration, award MVP017. This publication does not represent the views of the Department of Veteran Affairs or the United States Government. This manuscript has been authored by UT-Battelle, LLC under Contract No. DE-AC05-00OR22725 with the U.S. Department of Energy. The authors also acknowledge the support of the larger VA partnership, NIH grants U54-CA210180 (N.Y.R.A.), P41-EB028741 (N.Y.R.A.), and T32EB025823 (S.A.S.).